Clinical Significance of Soluble PD-1 and PD-L1 in Plasma of NSCLC Patients Treated with Immune Checkpoint Inhibitors

被引：0
|
作者：
Nakahara, Y. [1 ]
Himuro, H. [2 ]
Igarashi, Y. [2 ]
Kouro, T. [2 ]
Higashijima, N. [2 ]
Matsuo, N. [3 ]
Murakami, S.
Wei, F. [2 ]
Horaguchi, S. [2 ]
Tsuji, K. [2 ]
Mano, Y. [2 ]
Saito, H. [4 ]
Azuma, K. [3 ]
Naoki, K.
Sasada, T. [2 ]
机构：
[1] Kitasato Univ, Sch Med, Sagamihara, Kanagawa, Japan
[2] Kanagawa Canc Ctr Res Inst, Yokohama, Kanagawa, Japan
[3] Kurume Univ, Sch Med, Kurume, Fukuoka, Japan
[4] Kanagawa Canc Ctr, Yokohama, Kanagawa, Japan
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 11期
关键词：
Immune checkpoint inhibitors; Soluble PD-1; Soluble PD-L1;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP11.01-11
引用
收藏
页码：S614 / S614
页数：1
相关论文
共 50 条
  • [31] An update on companion and complementary diagnostic assays for PD-1/PD-L1 checkpoint inhibitors in NSCLC
    Jorgensen, Jan Trost
    EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2021, 21 (05) : 445 - 454
  • [32] Clinical significance of plasma MMPs and PD-1-binding soluble PD-L1 in gastric cancer and NSCLC treated with ICIs
    Ando, Fumihiko
    Kashiwada, Takeru
    Kuroda, Shoko
    Asatsuma, Tomoko
    Hashiguchi, Masaaki
    Kanazawa, Yoshikazu
    Ohashi, Ryuji
    Yoshida, Hiroshi
    Seike, Masahiro
    Gemma, Akihiko
    Iwai, Yoshiko
    CANCER SCIENCE, 2025, 116 : 696 - 696
  • [33] Significance of PD-L1 in Metastatic Urothelial Carcinoma Treated With Immune Checkpoint Inhibitors
    Maiorano, Brigida Anna
    Di Maio, Massimo
    Cerbone, Linda
    Maiello, Evaristo
    Procopio, Giuseppe
    Roviello, Giandomenico
    JAMA NETWORK OPEN, 2024, 7 (03) : E241215
  • [34] Stomach cancer. clinical significance of the expression of key components of pd-1/pd-l1 immune checkpoint
    Kovaleva, Olga V.
    Podlesnaya, Polina A.
    Gratchev, Alexei N.
    Chang, Victor L.
    Ognerubov, Nikolai A.
    Kushlinskii, Nikolai E.
    Journal of Nonlinear and Variational Analysis, 2021, 5 (03): : 122 - 127
  • [35] Prognostic Significance of PD-L1 Expression on Circulating Myeloid-Derived Suppressor Cells in NSCLC Patients Treated with Anti-PD-1/PD-L1 Checkpoint Inhibitors
    Salvia, Roser
    Rico, Laura G.
    Moran, Teresa
    Bradford, Jolene A.
    Ward, Michael D.
    Drozdowskyj, Ana
    Climent-Marti, Joan
    Martinez-Caceres, Eva M.
    Rosell, Rafael
    Petriz, Jordi
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (22)
  • [36] Measurement of soluble PD-1 and soluble PD-L1 as well as PD-L1 and PD-1 from perioperative patients with gastric carcinoma
    Wei, Hangzhi
    Wu, Fahong
    Mao, Yudong
    Zhang, Youcheng
    Leng, Guangxian
    Wang, Jia
    Zhang, Wei
    Wang, Tianwei
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2022, 52 (04) : 331 - 345
  • [37] PD-1/PD-L1 inhibitors
    Sunshine, Joel
    Taube, Janis M.
    CURRENT OPINION IN PHARMACOLOGY, 2015, 23 : 32 - 38
  • [38] Mycobacterial infections due to PD-1 and PD-L1 checkpoint inhibitors
    Anand, Kartik
    Sahu, Geetanjali
    Burns, Ethan
    Ensor, Allyne
    Ensor, Joe
    Pingali, Sai Ravi
    Subbiah, Vivek
    Iyer, Swaminathan P.
    ESMO OPEN, 2020, 5 (04)
  • [39] PD-1/PD-L1 immune checkpoint inhibitors in neoadjuvant therapy for solid tumors (Review)
    Tang, Quanying
    Zhao, Shikang
    Zhou, Ning
    He, Jinling
    Zu, Lingling
    Liu, Tingwen
    Song, Zuoqing
    Chen, Jun
    Peng, Ling
    Xu, Song
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2023, 62 (04)
  • [40] Drug Repurposing to Enhance Antitumor Response to PD-1/PD-L1 Immune Checkpoint Inhibitors
    Thuru, Xavier
    Magnez, Romain
    El-Bouazzati, Hassiba
    Vergoten, Gerard
    Quesnel, Bruno
    Bailly, Christian
    CANCERS, 2022, 14 (14)
12345